Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Calgary (Canada) to Investigate Oral Administration of Rose Bengal Disodium for Cancer Treatment
13 août 2020 08h00 HE
|
Provectus Biopharmaceuticals Inc.
University of Calgary researchers have successfully demonstrated initial, in vivo proof-of-concept, oral rose bengal disodium treatment for blood cancerResearchers will now investigate oral treatment...
Provectus Biopharmaceuticals Announces Acceptance of Two PV-10® Melanoma Cancer Abstracts at European Society for Medical Oncology (ESMO) Virtual Congress 2020
22 juil. 2020 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, July 22, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce that data from an ongoing clinical trial of investigational autolytic cancer immunotherapy PV-10...
Provectus Biopharmaceuticals Announces Change to Board of Directors
16 juil. 2020 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, July 16, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce the addition of Webster Bailey to the Company's Board of Directors (the “Board”), effective as...
Provectus Biopharmaceuticals Announces Discovery of Unique PV-10®-Induced STING Pathway Mechanism for Presentation at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II
22 juin 2020 07h30 HE
|
Provectus Biopharmaceuticals Inc.
PV-10 treatment leads to STING dimerizationResearchers identify potential association of heat shock proteins with STING in PV-10-treated models KNOXVILLE, TN, June 22, 2020 (GLOBE NEWSWIRE) --...
Provectus Biopharmaceuticals Expands Global Patent Portfolio to India for Cancer Combination Therapy
09 juin 2020 09h00 HE
|
Provectus Biopharmaceuticals Inc.
2020 India patent follows 2018 India patent that protects Provectus’ proprietary API manufacturing processProvectus further expands cancer combination therapy IP protection by filing new USPTO patent...
Provectus Announces Presentation of Updated Data from Metastatic Uveal Melanoma Cohort of Phase 1 PV-10® Study at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
01 juin 2020 09h00 HE
|
Provectus Biopharmaceuticals Inc.
Treatment refractory, immunologically cold, hepatic tumor type37% reduction and 83% stabilization of treated disease (2D-EASL)Overall survival of 11 months for checkpoint inhibition-naïve patients;...
Provectus Announces Publication of Updated Data from Metastatic Neuroendocrine Phase 1 PV-10® Study at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
01 juin 2020 07h00 HE
|
Provectus Biopharmaceuticals Inc.
Treatment refractory, immunologically cold, hepatic tumor type50% reduction of treated disease; 83% stabilization of overall patient disease (RECIST)Median progression-free survival not reached (by CT...
Provectus Announces PV-10® STING Agonist Abstract at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II
18 mai 2020 09h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, May 18, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce the publication of an abstract about and data from ongoing preclinical study of investigational...
Provectus Announces Acceptance of PV-10® Liver Cancer Abstracts at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
29 avr. 2020 16h30 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, April 29, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce that abstracts about and data from our clinical trials of investigational autolytic cancer...
Provectus Announces PV-10® Liver Cancer Presentation in ePoster Gallery of Society of Interventional Radiology (SIR) 2020 Annual Scientific Meeting
16 avr. 2020 17h30 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, April 16, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today said that data from its clinical trial of autolytic cancer immunotherapy PV-10 (rose bengal disodium) as a...